Asset Details
Do you wish to reserve the book?
Anti-tumor treatment and healthcare consumption near death in the era of novel treatment options for patients with melanoma brain metastases
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Anti-tumor treatment and healthcare consumption near death in the era of novel treatment options for patients with melanoma brain metastases
Do you wish to request the book?
Anti-tumor treatment and healthcare consumption near death in the era of novel treatment options for patients with melanoma brain metastases
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Anti-tumor treatment and healthcare consumption near death in the era of novel treatment options for patients with melanoma brain metastases
2022
Overview
Background
Effective systemic treatments have revolutionized the management of patients with metastatic melanoma, including those with brain metastases. The extent to which these treatments influence disease trajectories close to death is unknown. Therefore, this study aimed to gain insight into provided treatments and healthcare consumption during the last 3 months of life in patients with melanoma brain metastases.
Methods
Retrospective, single-center study, including consecutive patients with melanoma brain metastases diagnosed between June-2015 and June-2018, referred to the medical oncologist, and died before November-2019. Patient and tumor characteristics, anti-tumor treatments, healthcare consumption, presence of neurological symptoms, and do-not-resuscitate status were extracted from medical charts.
Results
100 patients were included. A
BRAF-
mutation was present in 66 patients. Systemic anti-tumor therapy was given to 72% of patients during the last 3 months of life, 34% in the last month, and 6% in the last week. Patients with a
BRAF-
mutation more frequently received systemic treatment during the last 3 (85% vs. 47%) and last month (42% vs. 18%) of life than patients without a
BRAF-
mutation. Furthermore, patients receiving systemic treatment were more likely to visit the emergency room (ER, 75% vs. 36%) and be hospitalized (75% vs. 36%) than those who did not.
Conclusion
The majority of patients with melanoma brain metastases received anti-tumor treatment during the last 3 months of life. ER visits and hospitalizations occurred more often in patients on anti-tumor treatment. Further research is warranted to examine the impact of anti-tumor treatments close to death on symptom burden and care satisfaction.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
/ Aged
/ Antineoplastic Agents - therapeutic use
/ Biomedical and Life Sciences
/ Brain Neoplasms - drug therapy
/ Emergency Medical Services - statistics & numerical data
/ Female
/ Health Promotion and Disease Prevention
/ Hospitalization - statistics & numerical data
/ Humans
/ Male
/ Melanoma
/ Methods
/ Mutation
/ Oncology
/ Patient Acceptance of Health Care - statistics & numerical data
/ Proto-Oncogene Proteins B-raf - genetics
We currently cannot retrieve any items related to this title. Kindly check back at a later time.